

CLINICAL RESEARCH

Outcomes and Effect of Treatment According to Etiology in HFrEF

An Analysis of PARADIGM-HF



Craig Balmforth, MBChB,^a Joanne Simpson, MBChB, PhD,^a Li Shen, MBChB, PhD,^a Pardeep S. Jhund, MBChB, MSc, PhD,^a Martin Lefkowitz, MD,^b Adel R. Rizkala, PHARM D,^b Jean L. Rouleau, MD,^c Victor Shi, MD,^b Scott D. Solomon, MD,^d Karl Swedberg, MD, PhD,^e Michael R. Zile, MD,^f Milton Packer, MD,^g John J.V. McMurray, MBChB, MD^a

ABSTRACT

OBJECTIVES The purpose of this study was to compare outcomes (and the effect of sacubitril/valsartan) according to etiology in the PARADIGM-HF (Prospective comparison of angiotensin-receptor-neprilysin inhibitor [ARNI] with angiotensin-converting-enzyme inhibitor [ACEI] to Determine Impact on Global Mortality and morbidity in Heart Failure) trial.

BACKGROUND Etiology of heart failure (HF) has changed over time in more developed countries and is also evolving in non-Western societies. Outcomes may vary according to etiology, as may the effects of therapy.

METHODS We examined outcomes and the effect of sacubitril/valsartan according to investigator-reported etiology in PARADIGM-HF. The outcomes analyzed were the primary composite of cardiovascular death or HF hospitalization, and components, and death from any cause. Outcomes were adjusted for known prognostic variables including N terminal pro-B type natriuretic peptide.

RESULTS Among the 8,399 patients randomized, 5,036 patients (60.0%) had an ischemic etiology. Among the 3,363 patients (40.0%) with a nonischemic etiology, 1,595 (19.0% of all patients; 47% of nonischemic patients) had idiopathic dilated cardiomyopathy, 968 (11.5% of all patients; 28.8% of nonischemic patients) had a hypertensive cause, and 800 (9.5% of all patients, 23.8% of nonischemic patients) another cause (185 infective/viral, 158 alcoholic, 110 valvular, 66 diabetes, 30 drug-related, 14 peripartum-related, and 237 other). Whereas the unadjusted rates of all outcomes were highest in patients with an ischemic etiology, the adjusted hazard ratios (HRs) were not different from patients in the 2 major nonischemic etiology categories; for example, for the primary outcome, compared with ischemic (HR: 1.00), hypertensive 0.87 (95% confidence interval [CI]: 0.75 to 1.02), idiopathic 0.92 (95% CI: 0.82 to 1.04) and other 1.00 (95% CI: 0.85 to 1.17). The benefit of sacubitril/valsartan over enalapril was consistent across etiologic categories (interaction for primary outcome; $p = 0.11$).

CONCLUSIONS Just under one-half of patients in this global trial had nonischemic HF with reduced ejection fraction, with idiopathic and hypertensive the most commonly ascribed etiologies. Adjusted outcomes were similar across etiologic categories, as was the benefit of sacubitril/valsartan over enalapril. (Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure; [NCT01035255](https://doi.org/10.1016/j.jchf.2019.02.015)) (J Am Coll Cardiol HF 2019;7:457-65)
© 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

From the ^aBHF Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom; ^bNovartis Pharmaceuticals Corporation, East Hanover, New Jersey; ^cMontreal Heart Institute and University of Montreal, Montreal, Quebec, Canada; ^dBrigham and Women's Hospital, Boston, Massachusetts; ^eUniversity of Gothenburg, Gothenburg, Sweden; ^fMedical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina; and the ^gBaylor University Medical Center, Dallas, Texas. Dr. Jhund has received personal fees from Novartis. Drs. Lefkowitz and Rizkala are employees of Novartis Pharmaceuticals. Dr. Rizkala owns Novartis stock. Dr. Rouleau has received personal fees from Novartis

**ABBREVIATIONS
AND ACRONYMS****ACEI** = angiotensin-converting enzyme inhibitor**AF** = atrial fibrillation**CV** = cardiovascular**EF** = ejection fraction**HF** = heart failure**HFrEF** = heart failure with reduced ejection fraction**LVEF** = left ventricular ejection fraction

The etiology of heart failure (HF) has changed over time in more developed countries and is also evolving in less developed and other non-Western societies (1-9). In the first report from the Framingham Heart Study, initiated in 1949 and published in 1971, hypertension was the most common etiology in patients recruited in the United States, although in that report HF was not subclassified by ejection fraction (EF) phenotype (1). More recently, in most reports, coronary heart disease has become the predominant cause of HF with reduced EF (HFrEF) (1-11). An epidemiologic transition has also occurred in Eastern Europe, Asia, and Africa from hypertension and rheumatic valvular disease to coronary heart disease (1-11).

SEE PAGE 466

Etiology is important for a number of reasons. First, outcome may vary according to etiology with nonischemic causes purported to carry a better prognosis than HF of ischemic origin (12,13). Second, specific etiologies may be an indication for specific therapies (e.g., bypass surgery for coronary artery disease) (14). Third, and more controversially, it has been suggested that the effectiveness of certain treatments for HFrEF may be modified by etiology (e.g., implantable cardiac defibrillator therapy in nonischemic cardiomyopathy and cardiac resynchronization therapy in ischemic compared with nonischemic HFrEF) (15,16).

To examine etiology in a contemporary and globally representative sample of patients with HFrEF, we examined investigator-reported cause of HF in the PARADIGM-HF (Prospective Comparison of angiotensin-receptor-neprilysin inhibitor

[ARNI] With angiotensin-converting-enzyme inhibitor [ACEI] to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial which enrolled 8399 patients in 47 countries on 6 continents (17-19). We also examined outcomes according to etiology, adjusting for a more extensive range of other prognostic variables, including natriuretic peptides, than in prior studies. Lastly, we also examined the effect of the angiotensin-receptor-neprilysin inhibitor sacubitril/valsartan compared with the ACEI enalapril, according to etiology.

METHODS

PATIENTS AND PROCEDURES. The design and primary results of PARADIGM-HF have been reported (17-19). Briefly, PARADIGM-HF was a randomized, double-blind comparison of sacubitril/valsartan with enalapril in patients with chronic HF and HFrEF. Eligibility criteria at screening included New York Heart Association (NYHA) functional class II to IV, left ventricular ejection fraction (LVEF) ≤ 40 [changed to ≤ 35 by amendment], and elevated natriuretic peptides. Exclusion criteria at screening included symptomatic hypotension or systolic blood pressure < 100 mm Hg, estimated glomerular filtration rate < 30 ml/min/1.73 m², and potassium > 5.2 mmol/l.

At trial entry, ongoing treatment with ACEI or angiotensin receptor blocker (ARB) was stopped and patients entered 2 sequential run-in periods, first receiving enalapril 10 mg twice daily for 2 weeks followed by sacubitril/valsartan for an additional 4 to 6 weeks, uptitrated from 49/51 mg to 97/103 mg twice daily. Patients tolerating both drugs at these target doses were randomly assigned to double-blind therapy with sacubitril/valsartan or enalapril in a 1:1 ratio.

and AstraZeneca. Dr. Solomon has received grants from Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol-Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lone Star Heart, Mesoblast, MyoKardia, NIH/NHLBI, Novartis, Sanofi, Pasteur, and Theracos; and has received personal fees from Akros, Alnylam, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Cardior, Corvia, Cytokinetics, Gilead, GlaxoSmithKline, Ironwood, Merck, Novartis, Roche, Takeda, Theracos, Quantum Genetics, Cardurion, AoBiome, Janssen, and Cardiac Dimensions. Dr. Swedberg has been a consultant to and received honoraria from AstraZeneca, Novartis, Pfizer, and Vifor Pharma. Dr. Zile has received personal fees from Novartis. Dr. Packer has received personal fees from Abbott, Amgen, Actavis, Bayer, Boehringer Ingelheim, Cardiorentis, Daiichi-Sankyo, Gilead, NovoNordisk, Relypsa, AstraZeneca, Sanofi, Synthetic Biologies, and Theravance. Dr. McMurray's employer, Glasgow University, has been paid by Novartis for time spent as Executive Committee member and then co-principal investigator of ATMOSPHERE, co-principal investigator of the PARADIGM-HF and PARAGON-HF trials, and Executive/Steering Committee member for PARADISE-MI and PERSPECTIVE trials (with sacubitril/valsartan) and meetings/presentations related to these trials and aliskiren and sacubitril/valsartan. Novartis has also paid his travel and accommodation for some of these meetings. These payments were made through a consultancy with Glasgow University and he has not received personal payments in relation to these trials/drugs. Drs. McMurray, Packer, Rouleau, Solomon, Swedberg, and Zile have participated in executive steering committee activities for clinical studies sponsored by Novartis. Drs. Jhund, McMurray and Zile are performing research sponsored by Novartis and they or their institutions have received consulting fees from Novartis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

The trial was approved by the ethics committees at each participating institution and all patients provided written informed consent.

INVESTIGATOR-REPORTED ETIOLOGY. The etiology of HF was collected by means of structured questions on the trial case report form. Investigators were first asked whether the primary etiology was ischemic or nonischemic. If the answer nonischemic was checked, investigators were then asked to specify from a number of options (listed in the following order): primary valvular (specify valve and surgery), alcoholic, hypertensive, idiopathic, peripartum, infectious cardiomyopathy, viral cardiomyopathy, diabetic, drug induced (specify type of drug), and “other” (please specify). For the purposes of this analysis, patients were categorized as ischemic or nonischemic, with nonischemic etiology further subcategorized into idiopathic, hypertensive and other, because the numbers of cases in “other” were individually too few to allow robust analysis.

OUTCOMES. The primary endpoint in PARADIGM-HF was a composite of cardiovascular (CV) death or HF hospitalization. In this study, we investigated the association between etiology and the risk of the primary outcome, each of its components, and all-cause mortality. All endpoints were adjudicated by a clinical endpoint committee in a blinded fashion. We also compared the effects of the randomized treatment on these outcomes, according to etiology, as described below.

Statistical analyses. Baseline characteristics are presented as frequencies and percentages for categorical variables and means with SD or medians with interquartile range for continuous variables. Differences in baseline characteristics were tested using chi-square test for categorical variables and analysis of variance or Kruskal-Wallis test for continuous variables.

Incidence rates for each outcome of interest are presented per 100 person-years of follow-up. Event rates in each etiologic category were estimated by the Kaplan-Meier method and compared using the log-rank test. Cox proportional hazards regression models were used to compare hazard ratios (HRs) with 95% confidence intervals according to etiology. In multivariable models, the HR was adjusted for the following baseline characteristics: age, sex, race, region, systolic blood pressure, heart rate, EF, NYHA functional class, history of HF hospitalization, duration of HF, atrial fibrillation (AF), body mass index, prior stroke, creatinine, randomized treatment (sacubitril/valsartan or enalapril), and log N terminal pro-B-type natriuretic peptide.

Analyses were performed using Stata version 13 (Stata Corp., College Station, Texas) and SAS version 9.4 (SAS Institute Inc., Cary, North Carolina). All p values are 2-sided, and a $p < 0.05$ was considered significant.

RESULTS

Of the total 8,399 patients randomized, 5,036 patients (60.0%) had an ischemic etiology and 3,363 patients (40.0%) had a nonischemic etiology. Among those with a nonischemic etiology, 1,595 patients (19.0% of all patients; 47% of nonischemic patients) were reported to have an idiopathic dilated cardiomyopathy, 968 (11.5% of all patients; 28.8% of nonischemic patients) a hypertensive cause and 800 (9.5% of all patients, 23.8% of nonischemic patients) another cause (185 infective/viral, 158 alcoholic, 110 valvular, 66 diabetes, 30 drug-related, 14 peripartum related, and 237 “other”).

BASELINE CHARACTERISTICS. The clinical characteristics of the patients categorized by etiology are shown in [Table 1](#). Patients with an ischemic (and hypertensive) etiology were older than those in the other nonischemic categories. Patients with an ischemic etiology were also more likely to be male and Caucasian. Nonischemic idiopathic patients were more frequently female and Asian (and nonischemic hypertensive patients were also more frequently female and black and less often Asian) than ischemic patients. Nonischemic patients were more often from Latin American and Asia, compared with ischemic patients.

LVEF was slightly but significantly lower in patients with idiopathic dilated cardiomyopathy compared to patients with an ischemic etiology and a hypertensive cause; however, natriuretic peptide concentrations did not differ meaningfully among the various etiologic categories.

History of myocardial infarction was more frequent in the ischemic group and hypertension and AF were each more common in the hypertensive etiology category. Conversely, history of diabetes was less frequent in the idiopathic group.

Investigator-reported etiology seemed to vary by geographic region. Ischemic etiology was most frequent in Central/Eastern Europe (70%) and least common in Latin America (43%) ([Online Table 1](#)). Among the nonischemic etiologies, hypertensive etiology was most common in Latin America (21% of all cases of HFrEF) and least common in the Asia-Pacific Region (6%), whereas idiopathic etiology was most common in the Asia Pacific Region (28%) and least common in Central/Eastern Europe and North

| TABLE 1 Baseline Characteristics According to Investigator-Reported Heart Failure Etiology | | | | | |
|---|-------------------------|---------------------------|---------------------------|--------------------|---------|
| | Ischemic (n = 5,036) | Nonischemic (N = 3,363) | | | p Value |
| | | Hypertensive (n = 968) | Idiopathic (n = 1,595) | Other (n = 800) | |
| Age, yrs | 65.7 ± 10.2 | 64.7 ± 11.5 | 60.0 ± 12.3 | 58.3 ± 12.6 | <0.001 |
| Female | 969 (19.2) | 283 (29.2) | 373 (29.2) | 207 (25.9) | <0.001 |
| Race or ethnic group | | | | | |
| White | 3,586 (71.2) | 607 (62.7) | 878 (55.1) | 473 (59.1) | <0.001 |
| Black | 110 (2.2) | 117 (12.1) | 97 (6.1) | 104 (13.0) | |
| Asian | 891 (17.7) | 89 (9.2) | 416 (26.1) | 113 (14.1) | |
| Other | 449 (8.9) | 155 (16.0) | 204 (12.8) | 110 (13.8) | |
| Region | | | | | |
| North America | 381 (7.6) | 65 (6.7) | 82 (5.1) | 74 (9.3) | <0.001 |
| Latin America | 617 (12.3) | 301 (31.1) | 308 (19.3) | 207 (25.9) | |
| Western Europe and other | 1,188 (23.6) | 231 (23.9) | 384 (24.1) | 248 (31.0) | |
| Central Europe | 1,987 (39.5) | 282 (29.1) | 399 (25.0) | 158 (19.8) | |
| Asia-Pacific | 863 (17.1) | 89 (9.19) | 422 (26.46) | 113 (14.12) | |
| SBP, mm Hg | 121.9 ± 15.2 | 126.6 ± 15.1 | 118.4 ± 15.0 | 117.6 ± 14.9 | <0.001 |
| HR, beats/min | 71.6 ± 11.8 | 74.3 ± 12.3 | 73.1 ± 11.8 | 73.1 ± 13.3 | <0.001 |
| BMI | 28.1 ± 5.3 | 29.4 ± 5.8 | 27.6 ± 5.9 | 28.2 ± 5.6 | <0.001 |
| Serum creatinine, mg/dl | 1.15 ± 0.3 | 1.10 ± 0.3 | 1.08 ± 0.3 | 1.10 ± 0.3 | <0.001 |
| Clinical features of HF | | | | | |
| EF, % | 30 ± 6.1 | 30.4 ± 6.0 | 28.0 ± 6.2 | 28.3 ± 6.5 | <0.001 |
| BNP, pg/ml | 254 (159-458) | 242 (146-463) | 251 (142-533) | 257 (139-481) | |
| NT-pro-BNP, pg/ml | 1,543 (850-2,981) | 1,793 (1,027-3,702) | 1,682 (910-3,595) | 1,791 (933-3,502) | |
| NYHA functional class | | | | | <0.001 |
| I | 201 (4.0) | 53 (5.5) | 82 (5.1) | 53 (6.6) | |
| II | 3,426 (68.0) | 686 (70.9) | 1,210 (75.9) | 597 (74.6) | |
| III | 1,359 (27.0) | 220 (22.7) | 295 (18.5) | 144 (18.0) | |
| IV | 41 (0.8) | 8 (0.8) | 7 (0.4) | 4 (0.5) | |
| Missing data | 9 (0.2) | 1 (0.1) | 1 (0.1) | 2 (0.25) | |
| Medical history | | | | | |
| Hypertension | 3,784 (75.1) | 955 (98.66) | 744 (48.5) | 427 (53.4) | <0.001 |
| Diabetes | 1,980 (39.3) | 307 (31.7) | 392 (24.6) | 228 (28.5) | <0.001 |
| Atrial fibrillation | 1,746 (34.7) | 439 (45.4) | 561 (35.2) | 345 (43.1) | <0.001 |
| Hospitalization for HF | 3,111 (61.8) | 586 (60.5) | 1,040 (65.2) | 537 (67.1) | 0.002 |
| Myocardial infarction | 3,537 (70.2) | 40 (4.1) | 31 (1.9) | 26 (3.3) | <0.001 |
| Stroke | 515 (10.2) | 82 (8.5) | 82 (5.1) | 46 (5.8) | <0.001 |
| Pre-trial use of ACE inhibitor | 3,964 (78.7) | 695 (71.8) | 1,227 (76.9) | 646 (80.8) | <0.001 |
| Pre-trial use of ARB | 1,089 (21.6) | 277 (28.6) | 371 (23.3) | 155 (19.4) | <0.001 |
| Prior PCI | 1,674 (33.2) | 34 (3.5) | 55 (3.5) | 38 (4.8) | <0.001 |
| Prior CABG | 1,274 (25.3) | 7 (0.7) | 8 (0.5) | 14 (1.8) | <0.001 |
| Treatments at randomization | | | | | |
| Diuretic | 3,932 (78.1) | 803 (83.0) | 1,339 (84.0) | 664 (83.0) | <0.001 |
| Digitalis | 1,252 (24.9) | 309 (31.9) | 653 (40.9) | 325 (40.6) | <0.001 |
| Beta-blocker | 4,695 (93.2) | 882 (91.1) | 1,502 (94.2) | 727 (91.50) | 0.008 |
| Mineralocorticoid antagonist | 2,643 (52.5) | 522 (53.9) | 1,002 (62.8) | 504 (63.0) | <0.001 |
| Statin | 3,560 (70.7) | 369 (38.1) | 556 (34.9) | 238 (29.8) | <0.001 |
| Antiplatelet | 3,476 (69.0) | 388 (40.1) | 587 (36.8) | 285 (35.6) | <0.001 |
| ICD | 832 (16.5) | 71 (7.33) | 222 (13.9) | 118 (14.8) | <0.001 |
| CRT | 324 (6.4) | 33 (3.4) | 146 (9.2) | 71 (8.9) | <0.001 |

Values are mean ± SD, n (%), or median (interquartile range).

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; BMI = body mass index; BNP = B-type natriuretic peptide; CABG = coronary artery bypass graft; CRT = cardiac resynchronization therapy; EF = ejection fraction; HF = heart failure; HR = heart rate; ICD = implantable cardioverter-defibrillator; NT-proBNP = N terminal-pro-B-type natriuretic peptide; NYHA = New York Heart Association; PCI = percutaneous coronary intervention; SBP = systolic blood pressure.

TABLE 2 Event Rates and Risks of the Primary Composite Endpoint of CV Mortality or HF Hospitalization, CV Mortality, HF Hospitalization, and All-Cause Mortality According to HF Etiology

| | N | Events | Crude Rate per 100 Patient-Years | Unadjusted HR (95% CI) | Adjusted HR* (95% CI) | p Value |
|----------------------------------|-------|--------|----------------------------------|------------------------|-----------------------|---------|
| Primary composite outcome | | | | | | |
| Ischemic | 5,036 | 1,272 | 12.31 (11.66-13.01) | 1.00 (reference) | 1.00 (reference) | |
| Nonischemic | | | | | | |
| Hypertensive | 968 | 211 | 10.41 (9.09-11.91) | 0.85 (0.73-0.98) | 0.87 (0.75-1.02) | 0.082 |
| Idiopathic | 1,595 | 357 | 10.95 (9.87-12.15) | 0.89 (0.79-1.00) | 0.92 (0.82-1.04) | 0.207 |
| Other | 800 | 191 | 11.96 (10.37-13.78) | 0.97 (0.83-1.13) | 1.00 (0.85-1.17) | 0.973 |
| CV mortality | | | | | | |
| Ischemic | 5,036 | 789 | 7.07 (6.60-7.58) | 1.00 (reference) | 1.00 (reference) | |
| Nonischemic | | | | | | |
| Hypertensive | 968 | 127 | 5.86 (4.92-6.97) | 0.83 (0.68-1.00) | 0.87 (0.72-1.06) | 0.168 |
| Idiopathic | 1,595 | 228 | 6.57 (5.77-7.48) | 0.93 (0.80-1.07) | 0.96 (0.82-1.12) | 0.616 |
| Other | 800 | 107 | 6.16 (5.10-7.44) | 0.87 (0.71-1.07) | 0.94 (0.76-1.16) | 0.581 |
| HF hospitalization | | | | | | |
| Ischemic | 5,036 | 725 | 7.02 (6.53-7.55) | 1.00 (reference) | 1.00 (reference) | |
| Nonischemic | | | | | | |
| Hypertensive | 968 | 122 | 6.02 (5.04-7.19) | 0.86 (0.71-1.04) | 0.91 (0.74-1.11) | 0.343 |
| Idiopathic | 1,595 | 221 | 6.78 (5.94-7.73) | 0.96 (0.83-1.12) | 1.02 (0.87-1.20) | 0.770 |
| Other | 800 | 127 | 7.95 (6.68-9.46) | 1.13 (0.93-1.36) | 1.13 (0.93-1.39) | 0.205 |
| All-cause mortality | | | | | | |
| Ischemic | 5,036 | 982 | 8.79 (8.26-9.36) | 1.00 (reference) | 1.00 (reference) | |
| Nonischemic | | | | | | |
| Hypertensive | 968 | 163 | 7.51 (6.44-8.76) | 0.85 (0.72-1.01) | 0.89 (0.75-1.06) | 0.186 |
| Idiopathic | 1,595 | 268 | 7.72 (6.85-8.71) | 0.88 (0.77-1.01) | 0.93 (0.81-1.08) | 0.349 |
| Other | 800 | 133 | 7.66 (6.46-9.07) | 0.87 (0.73-1.05) | 0.95 (0.79-1.15) | 0.623 |

*Adjusted for age, sex, race, region, systolic blood pressure, heart rate, ejection fraction, NYHA functional class, history of HF hospitalization, duration of HF, atrial fibrillation, body mass index, prior stroke, creatinine, randomized treatment, and log NT-proBNP.
 CI = confidence interval; CV = cardiovascular; other abbreviations as in Table 1.

America (both 14%). However, because the numbers in some of these subgroups were small, these analyses may not be robust, and the apparent variation reported requires further investigation in other datasets.

Treatment at baseline varied by etiology with digoxin use much more common in idiopathic patients (40.9%) compared to those with an ischemic etiology (24.9%).

Statin and antiplatelet therapy was used much more commonly in those with an ischemic etiology compared to all other etiologic categories.


OUTCOMES ACCORDING TO ETIOLOGY. The rate of the primary composite outcome, its components and all-cause mortality are shown in Table 2 and Figure 1. Although, the rate of all of these events was highest in patients with an ischemic etiology, the adjusted HR was not different from patients in the 2 major non-ischemic etiology categories (idiopathic and hypertensive). Repeating the analysis using any of history of myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, unstable angina, or angina to define the ischemic subgroup,

instead of investigator-reported ischemic etiology, gave almost identical results (Online Table 2).

EFFECT OF SACUBITRIL/VALSARTAN ACCORDING TO ETIOLOGY. The effect of sacubitril/valsartan, compared to enalapril, on the primary composite endpoint and CV death is shown in the Central Illustration. The benefit of sacubitril/valsartan was consistent across the etiologic categories (interaction p value for primary endpoint = 0.11; for CV death = 0.55).

DISCUSSION


In the largest and most globally representative trial to date in patients with HFrEF, we found that the most common etiology was ischemic heart disease (in 60% of participants), although this varied with sex, race, and geographic region. Gheorghide et al. (20) reported in a review of 24 trials published between 1986 and 2005 that 62% of patients had an investigator-reported ischemic etiology and this coronary disease and in more recent trials the proportion has varied between 65% and 70% in studies with a high

FIGURE 1 Cumulative Incidence of Outcome According to Etiology (Ischemic, Idiopathic, Hypertensive, and Other)**(A)** Cumulative incidence of primary composite outcome, **(B)** cardiovascular mortality, **(C)** heart failure hospitalization, and **(D)** all-cause mortality according to etiology (ischemic, idiopathic, hypertensive, and other).

proportion of European patients (especially from Central/Eastern Europe) to 56% in another large global trial with significant numbers of patients from Asia and Latin America (19-23). Of the nonischemic etiologies reported, by far the largest category was idiopathic (47% of nonischemic cases) and another 29% of cases were ascribed a hypertensive etiology. Few prior studies have subcategorized etiology beyond ischemic and nonischemic. Felker et al. (24) studied 1,230 patients who underwent endomyocardial biopsy between December 1982 and December 1997 at Johns Hopkins Hospital, as part of an evaluation for HF due to unexplained cardiomyopathy. In that highly selected cohort, 616 patients were diagnosed with an idiopathic cardiomyopathy (24) and other etiologies were identified in much smaller number of patients including myocarditis (n = 111),

HIV infection (n = 45), hypertension (n = 49), peripartum cardiomyopathy (n = 51), infiltrative myocardial disease (n = 59), connective tissue disease (n = 39), substance abuse (n = 37), doxorubicin therapy (n = 15), and other (n = 117); in addition, 91 patients had (unexpected) ischemic heart disease. In a more representative study, Pecini et al. (25) examined data from 3,078 hospitalized patients screened between 2001 and 2002 for inclusion in a clinical trial in Denmark. Overall, 1,924 (63%) of these patients had an LVEF <45%. Six major etiologic groups were identified by investigators: ischemic heart disease (n = 925; 48.1%), idiopathic dilated cardiomyopathy (n = 223; 11.6%), hypertension (n = 204; 10.6%), valvular heart disease (n = 165; 8.6%), other (n = 183; 9.5%), and unknown/mixed (n = 224; 11.6%). Our findings are broadly in keeping with these Danish

CENTRAL ILLUSTRATION Effect of Sacubitril/Valsartan According to Etiology of Heart Failure



Balmforth, C. et al. *J Am Coll Cardiol HF*. 2019;7(6):457-65.

Effect of randomized therapy with sacubitril/valsartan (sac/val) or enalapril on the primary composite outcome (A), or cardiovascular mortality (B) according to etiology (ischemic, idiopathic, hypertensive, and other). There was no significant treatment by etiology interaction. CI = confidence interval; HR = hazard ratio.

data, although an ischemic etiology was more common, overall, and valvular etiology less frequent, in participants in PARADIGM-HF.

In keeping with prior reports, patients in PARADIGM-HF with an ischemic etiology had a higher crude incidence of adverse outcomes (12,13,25). However, in contrast to previous findings, when adjusted for other prognostic variables, including we believe for the first time natriuretic peptides, outcomes in PARADIGM-HF did not differ by etiology (at least for the 3 largest categories—ischemic, idiopathic, and hypertensive). In the 2 earlier studies mentioned above, the

multivariable models used adjusted for few variables and did not include natriuretic peptides in either case. Moreover, evidence-based life-saving therapies were not reported (Felker et al. [24]) or underused (Pecini et al. [25]) in the aforementioned studies, which were conducted before or at the beginning of the beta-blocker era in management of HF_rEF. Consequently, it would appear that in contemporary practice, mortality and morbidity are broadly similar across the most common HF_rEF etiologies when other prognostic variables are adjusted for. We cannot be certain whether this is also true for the less common etiologies and it remains possible that

among patients labelled as having an idiopathic dilated cardiomyopathy there may be subgroups of patients defined by genetic or other variables that fare better or worse than the rest.

In a developing era of precision medicine, more detailed phenotyping (and genotyping) of patients has been advocated to target treatments to patients more likely to benefit (26). Etiology is one aspect of phenotyping which may help determine choice of therapy. Surgical revascularization improves outcomes in selected patients with coronary artery disease and implantable cardioverter therapy may be less effective in patients with nonischemic dilated cardiomyopathy (14,15). Other biomarkers and comorbidities may identify patients more or less likely to benefit from specific drug therapies; for example, ivabradine is effective in patients with a higher heart rate and beta-blockers may be less effective in patients in AF (23,27). In the acute setting, the efficacy and safety of intravenous milrinone appeared to be modified by etiology— with worse treatment-related outcomes in patients with an ischemic etiology and better outcomes in nonischemic patients (28). On the other hand, other treatments such as ACEIs, ARBs and mineralocorticoid receptor antagonists appear equally effective across all phenotypic subgroups examined. We have previously reported that sacubitril/valsartan is similarly effective in subgroups defined by comorbidity and biomarkers (blood pressure, heart rate, natriuretic peptides, and estimated glomerular filtration rate) (19,29-32). Here we show a benefit irrespective of etiology (at least across the major etiologic categories identified by investigators).

STUDY LIMITATIONS. As with any study of this type, there are limitations. The analyses conducted were not pre-planned and the patients analyzed were those enrolled on a clinical trial rather than an unselected community cohort. Etiology was investigator-reported and no specific instructions were provided as to how to identify etiology. Patients may not have been exhaustively investigated for specific causes of HF, and some degree of etiologic misclassification will have occurred. The difficulties of ascribing a coronary etiology, even with angiography, have been discussed (33). It was not possible to examine outcomes in nonischemic etiologic categories other than the idiopathic and hypertensive groups because of small numbers. Similarly, it would have been of interest to study subcategories of CV mortality according to etiology, but this was also impossible because of the small numbers of events.

CONCLUSIONS

In summary, in PARADIGM-HF, the most common HFrEF etiology was ischemic heart disease (in 60% of participants). Of the nonischemic etiologies reported, the largest category was idiopathic (47% of nonischemic cases) and another 29% of patients were ascribed a hypertensive etiology. When adjusted for other prognostic variables, including natriuretic peptides, outcomes were similar across etiologic categories. The benefit of sacubitril/valsartan over enalapril was not modified by etiology.

ADDRESS FOR CORRESPONDENCE: Dr. John J.V. McMurray, British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, United Kingdom. E-mail: john.mcmurray@glasgow.ac.uk.

PERSPECTIVES

COMPETENCY IN MEDICAL KNOWLEDGE:

Although globally an ischemic etiology is the most commonly reported cause of HFrEF, approximately 40% of cases have a nonischemic etiology. How outcomes vary according to etiology in contemporary cohorts and whether etiology modifies response to therapy in HFrEF is of interest. Although patients with an investigator-reported ischemic etiology had worse outcomes than those with a nonischemic etiology, neither the unadjusted nor adjusted risk was significantly different between these 2 groups. Outcomes did not differ, either, between the 2 major nonischemic subgroups; those being hypertensive and idiopathic etiology. The benefit of sacubitril/valsartan, compared with enalapril, was consistent across etiologic category.

TRANSLATIONAL OUTLOOK:

Although there may be some misclassification of cause of HF in studies using investigator-reported etiology, the present analysis suggests no major difference in outcomes according to etiology in patients treated with contemporary therapies and that etiology does not modify the response to sacubitril/valsartan. Once HFrEF is established, left ventricular systolic dysfunction and the resultant maladaptive compensatory responses, rather than underlying cause, may become the main determinants of outcome in patients. Treatments targeted at these pathophysiologic abnormalities may also be equally effective, irrespective of etiology.

REFERENCES

1. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. *N Engl J Med* 1971;285:1441-6.
2. Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the development of congestive heart failure. The Framingham study. *N Engl J Med* 1972;287:781-7.
3. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. *J Am Coll Cardiol* 1993;22 4 suppl A: 6A-13A.
4. Mahmood SS, Wang TJ. The epidemiology of congestive heart failure: the Framingham Heart Study perspective. *Glob Heart* 2013;8:77-82.
5. Callender T, Woodward M, Roth G, et al. Heart failure care in low- and middle-income countries: a systematic review and meta-analysis. *PLoS Med* 2014;11:e1001699.
6. Glezeva N, Gallagher J, Ledwidge M, et al. Heart failure in sub-Saharan Africa: review of the aetiology of heart failure and the role of point-of-care biomarker diagnostics. *Trop Med Int Health* 2015;20:581-8.
7. Zhang Y, Zhang J, Butler J, et al. contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the China Heart Failure (China-HF) registry. *J Card Fail* 2017;23:868-75.
8. Lam CS, Teng TK, Tay WT, et al. Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry. *Eur Heart J* 2016;37:3141-53.
9. Dokainish H, Teo K, Zhu J, et al. Heart failure in Africa, Asia, the Middle East and South America: the INTER-CHF study. *Int J Cardiol* 2016;204:133-41.
10. Kumbhani DJ, Fonarow GC, Heidenreich PA, et al. association between hospital volume, processes of care, and outcomes in patients admitted with heart failure: insights from Get With The Guidelines-Heart Failure. *Circulation* 2018;137:1661-70.
11. Canepa M, Fonseca C, Chioncel O, et al. performance of prognostic risk scores in chronic heart failure patients enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. *J Am Coll Cardiol* 2018;6:452-62.
12. Frazier CG, Alexander KP, Newby LK, et al. Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials. *J Am Coll Cardiol* 2007;49:1450-8.
13. Martínez-Sellés M, Doughty RN, Poppe K, et al. Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis. *Eur J Heart Fail* 2012;14:473-9.
14. Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. *N Engl J Med* 2016;374:1511-20.
15. Køber L, Thune JJ, Nielsen JC, et al. defibrillator implantation in patients with nonischemic systolic heart failure. *N Engl J Med* 2016;375:1221-30.
16. Linde C, Abraham WT, Gold MR, Daubert C, REVERSE Study Group. Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (Resynchronization reVERses Remodeling in Systolic Left vEntricular Dysfunction) study. *J Am Coll Cardiol* 2010;56:1826-31.
17. McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). *Eur J Heart Fail* 2013;15:1062-73.
18. McMurray JJ, Packer M, Desai AS, et al. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). *Eur J Heart Fail* 2014;16:817-25.
19. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med* 2014;371:993-1004.
20. Gheorghade M, Sopko G, De Luca L, et al. Navigating the crossroads of coronary artery disease and heart failure. *Circulation* 2006;114:1202-13.
21. McMurray JJ, Krum H, Abraham WT, et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. *N Engl J Med* 2016;374:1521-32.
22. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med* 2011;364:11-21.
23. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. *Lancet* 2010;376:875-85.
24. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. *N Engl J Med* 2000;342:1077-84.
25. Pecini R, Møller DV, Torp-Pedersen C, Hassager C, Køber L. Heart failure etiology impacts survival of patients with heart failure. *Int J Cardiol* 2011;149:211-5.
26. Zannad F. Pharmacotherapy in heart failure with reduced ejection fraction during the last 20 years, and the way ahead for precision medicine. *Eur Heart J Cardiovasc Pharmacother* 2015;1:10-2.
27. Kotecha D, Holmes J, Krum H, et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. *Lancet* 2014;384:2235-43.
28. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. *J Am Coll Cardiol* 2003;41:997-1003.
29. Böhm M, Young R, Jhund PS, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. *Eur Heart J* 2017;38:1132-43.
30. Okumura N, Jhund PS, Gong J, et al. Effects of sacubitril/valsartan in the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy. *Circ Heart Fail* 2016;9:e003212.
31. Zile MR, Claggett BL, Prescott MF, et al. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. *J Am Coll Cardiol* 2016;68:2425-36.
32. Damman K, Gori M, Claggett B, et al. renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. *J Am Coll Cardiol HF* 2018;6:489-98.
33. Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. *J Am Coll Cardiol* 2002;39:210-8.

KEY WORDS angiotensin receptor blocker, angiotensin-converting enzyme inhibitor, etiology, heart failure, natriuretic peptides, neprilysin, treatment

APPENDIX For supplemental tables, please see the online version of this paper.